BioArctic develops new treatment for Gaucher’s disease
Stockholm, November 8, 2022 – BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced that the company has initiated a new project focused on enzyme replacement therapy for Gaucher’s disease in combination with the company’s Brain Transporter technology. Today there is no treatment available for neuropathic Gaucher’s disease and BioArctic’s aim is to develop a therapy which also affects the neuropathic manifestation of the disease.Gaucher’s disease is a rare genetic disorder in which a reduced function of the enzyme glucocerebrosidase leads to accumulation of glycolipids in certain